Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

Jung Yun Lee, Sunghoon Kim, YoungTae Kim, Myong Cheol Lim, Boram Lee, Kyu Won Jung, Jae Weon Kim, Sang Yoon Park, Young Joo Won

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P<0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P<0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P=0.189 and P=0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.

Original languageEnglish
Article number601
JournalBMC cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 May 29

Fingerprint

Ovarian Neoplasms
Survival
Survival Rate
Endometrioid Carcinoma
Carcinoma
Therapeutics
Korea
Proportional Hazards Models
Registries
Multivariate Analysis
Demography
Drug Therapy
Ovarian epithelial cancer
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Lee, Jung Yun ; Kim, Sunghoon ; Kim, YoungTae ; Lim, Myong Cheol ; Lee, Boram ; Jung, Kyu Won ; Kim, Jae Weon ; Park, Sang Yoon ; Won, Young Joo. / Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. In: BMC cancer. 2018 ; Vol. 18, No. 1.
@article{11d89f973e4747aa905fccc0dc038924,
title = "Changes in ovarian cancer survival during the 20 years before the era of targeted therapy",
abstract = "Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2{\%} during 1995-1999 to 63.8{\%} during 2010-2014 (P<0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P<0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P=0.189 and P=0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.",
author = "Lee, {Jung Yun} and Sunghoon Kim and YoungTae Kim and Lim, {Myong Cheol} and Boram Lee and Jung, {Kyu Won} and Kim, {Jae Weon} and Park, {Sang Yoon} and Won, {Young Joo}",
year = "2018",
month = "5",
day = "29",
doi = "10.1186/s12885-018-4498-z",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Lee, JY, Kim, S, Kim, Y, Lim, MC, Lee, B, Jung, KW, Kim, JW, Park, SY & Won, YJ 2018, 'Changes in ovarian cancer survival during the 20 years before the era of targeted therapy', BMC cancer, vol. 18, no. 1, 601. https://doi.org/10.1186/s12885-018-4498-z

Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. / Lee, Jung Yun; Kim, Sunghoon; Kim, YoungTae; Lim, Myong Cheol; Lee, Boram; Jung, Kyu Won; Kim, Jae Weon; Park, Sang Yoon; Won, Young Joo.

In: BMC cancer, Vol. 18, No. 1, 601, 29.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

AU - Lee, Jung Yun

AU - Kim, Sunghoon

AU - Kim, YoungTae

AU - Lim, Myong Cheol

AU - Lee, Boram

AU - Jung, Kyu Won

AU - Kim, Jae Weon

AU - Park, Sang Yoon

AU - Won, Young Joo

PY - 2018/5/29

Y1 - 2018/5/29

N2 - Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P<0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P<0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P=0.189 and P=0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.

AB - Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P<0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P<0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P=0.189 and P=0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.

UR - http://www.scopus.com/inward/record.url?scp=85047738158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047738158&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4498-z

DO - 10.1186/s12885-018-4498-z

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 601

ER -